Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential vs Concurrent Trastuzumab with Anthracyclines in HER2+ Breast Cancer
NCT00513292Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2007
- Primary completion
- Jun 2012
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of trastuzumab in HER2-positive breast cancer, sponsored by National Cancer Institute. Started Jul 2007; status: completed.
02
Drugs
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT00513292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00513292.